(Q42485313)

1 November 2017

Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients (English)

1 reference

1 November 2017

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

arterial hypertension

1 reference

Alfonso De Stefano

1

1 reference

1 November 2017

Chiara Carlomagno

2

1 reference

1 November 2017

Stefano Pepe

3

1 reference

1 November 2017

Roberto Bianco

4

1 reference

1 November 2017

Sabino De Placido

5

1 reference

1 November 2017

16 March 2011

1 reference

Cancer Chemotherapy and Pharmacology

1 November 2017

1 reference

1 November 2017

68

1 reference

1 November 2017

5

1 reference

1 November 2017

1207-1213

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1604-1

1 November 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Attenuation of the microcirculation in young patients with high-output borderline hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1604-1

10.1007/S00280-011-1604-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 November 2017

0 references

1 reference